{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:43:22Z","timestamp":1785156202985,"version":"3.55.0"},"reference-count":25,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","award":["NNF20OC0060561"],"award-info":[{"award-number":["NNF20OC0060561"]}],"id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2022,11,3]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The role of hyperuricaemia as a prognostic maker has been established in chronic heart failure (HF) but limited information on the association between plasma uric acid (UA) levels and central haemodynamic measurements is available.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective study on patients with advanced HF referred for right heart catherisation. Regression analyses were constructed to investigate the association between UA and haemodynamic variables. Cox models were created to investigate if UA was a significant predictor of adverse outcome where log1.1(UA) was used to estimate the effect on outcome associated with a 10% increase in UA levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 228 patients were included (77% males, age 49\u00b112 years, mean left ventricular ejection fraction (LVEF) of 17%\u00b18%). Median UA was 0.48 (0.39\u20130.61) mmol\/L. UA level was associated to pulmonary capillary wedge pressure (PCWP) and cardiac index (CI) in univariable (both p&lt;0.001) and multivariable regression analysis (p&lt;0.004 and p=0.025 for PCWP and CI). When constructing multivariable Cox models including PCWP, CI, central venous pressure, age, estimated glomerular filtration rate (eGFR), use of loop diuretics and LVEF, log1.1(UA) independently predicted the combined endpoint (left ventricular assist device, total artificial heart implantation, heart transplantation or all-cause mortality) (hazard ratio (HR): 1.10 (1.03\u20131.17), p=0.004) as well as all-cause mortality (HR: 1.15 (1.06\u20131.25), p=0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Elevated UA is associated with greater haemodynamic impairment in advanced HF. In adjusted Cox models (age, eGFR, LVEF and haemodynamics), UA predicts the combined endpoint and all-cause mortality in long-term follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2022-002092","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T09:30:25Z","timestamp":1669368625000},"page":"e002092","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Uric acid in advanced heart failure: relation to central haemodynamics and outcome"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1837-6538","authenticated-orcid":false,"given":"Tania","family":"Deis","sequence":"first","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper","family":"Rossing","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads Kristian","family":"Ersb\u00f8ll","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Wolsk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Herlev-Gentofte, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"2025081711045771000_9.2.e002092.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2008.09.006"},{"key":"2025081711045771000_9.2.e002092.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(00)00141-0"},{"key":"2025081711045771000_9.2.e002092.3","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cardfail.2020.08.015","article-title":"Uric acid is a biomarker of oxidative stress in the failing heart: lessons learned from trials with allopurinol and SGLT2 inhibitors","volume":"26","author":"Packer","year":"2020","journal-title":"J Card Fail"},{"key":"2025081711045771000_9.2.e002092.4","doi-asserted-by":"crossref","first-page":"330","DOI":"10.12669\/pjms.332.11779","article-title":"Serum uric acid level in the severity of congestive heart failure (CHF)","volume":"33","author":"Khan","year":"2017","journal-title":"Pak J Med Sci"},{"key":"2025081711045771000_9.2.e002092.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2011.00200.x"},{"key":"2025081711045771000_9.2.e002092.6","doi-asserted-by":"crossref","first-page":"785327","DOI":"10.3389\/fmed.2021.785327","article-title":"Serum uric acid and risk of chronic heart failure: a systematic review and meta-analysis","volume":"8","author":"Miao","year":"2021","journal-title":"Front Med"},{"key":"2025081711045771000_9.2.e002092.7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2025081711045771000_9.2.e002092.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.13368299"},{"key":"2025081711045771000_9.2.e002092.9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1751-7133.2010.00205.x","article-title":"Serum uric acid levels correlate with filling pressures in systolic heart failure","volume":"17","author":"Amin","year":"2011","journal-title":"Congest Heart Fail"},{"key":"2025081711045771000_9.2.e002092.10","doi-asserted-by":"crossref","DOI":"10.15420\/cfr.2022.09","article-title":"Aortic Pulsatility index: a new haemodynamic measure with prognostic value in advanced heart failure","volume":"8","author":"Deis","year":"2022","journal-title":"Card Fail Rev"},{"key":"2025081711045771000_9.2.e002092.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"2025081711045771000_9.2.e002092.12","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jch.13210","article-title":"Serum uric acid is associated with incidence of heart failure with preserved ejection fraction and cardiovascular events in patients with arterial hypertension","volume":"20","author":"Gu","year":"2018","journal-title":"J Clin Hypertens"},{"key":"2025081711045771000_9.2.e002092.13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.numecd.2019.12.008","article-title":"Asymptomatic hyperuricemia and incident congestive heart failure in elderly patients without comorbidities","volume":"30","author":"Wu","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025081711045771000_9.2.e002092.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.08.006"},{"key":"2025081711045771000_9.2.e002092.15","first-page":"556","article-title":"Hyperuricemia and incident heart failure","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circulation"},{"key":"2025081711045771000_9.2.e002092.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2009.01.010"},{"key":"2025081711045771000_9.2.e002092.17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehq473"},{"key":"2025081711045771000_9.2.e002092.18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2016.11.077","article-title":"Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure","volume":"228","author":"Otaki","year":"2017","journal-title":"Int J Cardiol"},{"key":"2025081711045771000_9.2.e002092.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.01.068"},{"key":"2025081711045771000_9.2.e002092.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014536"},{"key":"2025081711045771000_9.2.e002092.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.868604"},{"key":"2025081711045771000_9.2.e002092.22","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"key":"2025081711045771000_9.2.e002092.23","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ejhf.2433","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025081711045771000_9.2.e002092.24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025081711045771000_9.2.e002092.25","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1016\/j.jacc.2020.10.005","article-title":"Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction","volume":"76","author":"Omar","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2022-002092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T18:05:06Z","timestamp":1755453906000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2022-002092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,11,25]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/openhrt-2022-002092"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2022-002092","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}